The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Observation prior to systemic therapy in patients with metastatic renal cell carcinoma in the kinase inhibitor era.
R. A. Fisher
No relevant relationships to disclose
A. Pender
No relevant relationships to disclose
K. Thillai
No relevant relationships to disclose
S. Chowdhury
No relevant relationships to disclose
L. M. Pickering
Other Remuneration - Bayer; Novartis; Pfizer
S. St. Rose
No relevant relationships to disclose
M. E. Gore
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
J. M. G. Larkin
Consultant or Advisory Role - Bayer; GlaxoSmithKline; Novartis; Pfizer
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bayer; Novartis; Pfizer